Philip Morris International (PMI) is selling inhaled drug specialist Vectura to Molex Asia Holdings for a fraction of the £1.1 billion ($1.45 billion) it paid for the business three years a
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
Researchers have found that changes in speech recorded using a smartphone can be used to predict when a patient with chronic obstructive pulmonary disease (COPD) is at risk of an exacerbati
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS
Flagship Pioneering has signed yet another strategic-level deal with a big pharma group, with GSK the latest to tap into its network of biotech companies in an alliance that could be worth
Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year